Metosuccinat Sandoz (Metoprolol Succinate)

Metosuccinat Sandoz is a beta‑blocker that acts on the cardiovascular system to control blood pressure and reduce cardiac workload.

• Hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Chronic heart failure: improves survival and reduces hospitalisation by decreasing heart rate and contractility.
• Post‑myocardial infarction prophylaxis: reduces the chance of recurrent infarction and arrhythmias.
• Certain cardiac arrhythmias: helps control ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, leading to reduced cyclic AMP formation, decreased intracellular calcium, and consequently lower heart rate, myocardial contractility, and renin release. This results in diminished cardiac output and peripheral vascular resistance, helping to control blood pressure and relieve myocardial oxygen demand.

Metosuccinat Sandoz may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Dizziness or light‑headedness, especially on standing.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea, abdominal discomfort.
• Depression or mood changes.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Acute hypotension with fainting or shock.
• Bronchospasm in patients with asthma or COPD.
• Worsening heart failure or pulmonary edema.
• Allergic reactions such as rash, itching, or angio‑edema.
• Cardiogenic shock in rare cases.

Before initiating Metosuccinat Sandoz, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Monitor heart rate and blood pressure: adjust dose if excessively low.
• Assess renal and hepatic function: dose may need modification in impairment.
• Use caution in asthma or chronic obstructive pulmonary disease: β1‑selectivity may not fully prevent bronchospasm.
• Avoid abrupt discontinuation: taper gradually to prevent rebound hypertension or tachycardia.
• Adjust dose in diabetic patients: may mask hypoglycaemia symptoms.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metosuccinat Sandoz can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Verapamil or diltiazem: additive negative chronotropic effect may cause severe bradycardia.
• Clonidine abrupt withdrawal: can precipitate severe hypertension.
• Potent CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase metoprolol plasma levels, raising risk of toxicity.

Moderate Interactions (Monitor Closely)

• Diuretics or ACE inhibitors: may enhance hypotensive effect.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can reduce antihypertensive efficacy.
• Insulin or oral hypoglycemics: monitor glucose as beta‑blockade may mask hypoglycaemia signs.
• Other antihypertensives: additive blood pressure lowering.
• Antiarrhythmic agents (e.g., amiodarone): may increase risk of conduction abnormalities.